Combined ranitidine and pirenzepine in the treatment of duodenal ulcer: a multicentre double-blind study using endoscopy
| Autor: | V. Benvestito, A. Ferrara, Alberto Prada, G. Bensi, P.R. Dal Monte, G.M. Claar, L. Santoro, L. Cipolletta, A. Battocchia, Gabriele Mazzacca, Cremonini R, Enrico Colombo, G. Iaquinto, G. Bianchi Porro, Guido Piai, M. Lazzaroni, R. Venturelli |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Adult
Male Analgesic 030204 cardiovascular system & hematology Placebo Ranitidine Biochemistry law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial Histamine H2 receptor Double-Blind Method Oral administration law medicine Humans Duodenoscopy business.industry Biochemistry (medical) Cell Biology General Medicine Pirenzepine medicine.anatomical_structure 030220 oncology & carcinogenesis Anesthesia Duodenal Ulcer Duodenum Drug Therapy Combination Female business medicine.drug |
| Zdroj: | The Journal of international medical research. 18(5) |
| ISSN: | 0300-0605 |
| Popis: | The efficacy of a combination of ranitidine and pirenzepine in the short-term treatment of duodenal ulcer was evaluated in a double-blind trial. In a multicentre study, 352 patients with active duodenal ulcers were randomly allocated to be treated with 300 mg/day ranitidine plus placebo (group I), 300 mg/day ranitidine plus 50 mg/day pirenzepine (group II), or 300 mg/day ranitidine plus 100 mg/day pirenzepine (group III) for 4 weeks. The respective healing rates assessed using endoscopic examination after 2 and 4 weeks' treatment were 40% and 70% in group I, 44% and 82% in group II, and 37% and 77% in group III. The differences between the treatment groups were not significant, although 300 mg/day ranitidine plus 50 mg/day pirenzepine tended to be superior to the other treatments. Analgesic activity was the same in the three groups with 33%, 34% and 33% reductions, respectively, in the numbers of patients experiencing pain after 2 weeks. Side-effects (mainly dry mouth and blurred vision) were significantly more frequent in group III patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|